Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy by Straub V et al.
Policy view 
Cooperation among stakeholders to overcome challenges in orphan medicine development 
The example of Duchenne muscular dystrophy  
Volker Straub, MD1, Pavel Balabanov, PhD2, Kate Bushby, MD1, Monica Ensini, PhD1, Nathalie 
Goemans, MD3, Annamaria De Luca, PhD4, Alejandra Pereda5, Robert Hemmings6, Giles 
Campion, MD7, Edward Kaye, MD8, Virginia Arechavala-Gomeza, PhD9, Aurelie Goyenvalle, 
PhD10, Erik Niks, MD11, Olav Veldhuizen1, Pat Furlong12, Violeta Stoyanova-Beninska, MD13, 
Matthew J. Wood, PhD14, Alex Johnson15, Eugenio Mercuri, MD16, Francesco Muntoni, MD17, 
Bruno Sepodes, PhD18, Manuel Haas, PharmD2, Elizabeth Vroom, DMD19 and Annemieke 
Aartsma-Rus, PhD1,11 
1John Walton Muscular Dystrophy Research Centre and MRC Centre for Neuromuscular 
Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK  
2European Medicines Agency, Human medicines evaluation division, Scientific and regulatory 
management department, CNS and Ophthalmology office, London, UK 
3Department of Child Neurology, University Hospitals Leuven, Leuven, Belgium 
4Unit of Pharmacology, Department of Pharmacy – Drug Sciences, University of Bari, Bari, Italy 
5Duchenne Parent Project, Madrid, Spain  
6Medicines and Healthcare Product Regulatory Agency, London, UK 
  
7BioMarin Pharmaceutical Inc., Developmental Sciences, Novato, CA, USA 
8Sarepta Therapeutics, Cambridge, MA, US 
9Neuromuscular Disorders Group, BioCruces Health Research Institute, Barakaldo, Spain 
10Université de Versailles Saint Quentin en Yvelines, Inserm U1179, Montigny le bretonneux, 
France 
11Leiden University Medical Center, Leiden, the Netherlands 
12Parent Project Muscular Dystrophy, Hackensack NJ, US 
13Medicines Evaluation Board, Utrecht, The Netherlands 
14Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK 
15Joining Jack, UK 
16Pediatric Neurology, Catholic University, Rome, Italy 
2 
 
17 Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Diseases, UCL Institute 
of Child Health & Great Ormond Street Hospital, London, UK 
18Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal 
19United Parent Projects Muscular Dystrophy, Amsterdam, the Netherlands 
 
Corresponding author 
Annemieke Aartsma-Rus, PhD 
Department of Human Genetics 
Leiden University Medical Center 
Albinusdreef 2 
2333 ZA Leiden 
The Netherlands 
Tel +31 715269436 






Duchenne muscular dystrophy (DMD) is a rare, progressive muscle-wasting disease leading to 
severe disability and premature death. Treatment is currently symptomatic, but multiple 
experimental therapies are in development. Implemented care standards, validated outcome 
measures correlating with clinical benefit, and comprehensive information about the natural 
history of the disease are essential for the regulatory approval of any therapy. However, for 
DMD and other rare diseases, these are not always in place when potential therapies enter the 
clinical trial phase. A cooperative effort of DMD stakeholders, including representatives from 
patient groups, academia, industry and regulatory agencies aimed at addressing this by 
identifying strategies to overcome challenges, developing the tools required and collecting 
relevant data. This review illustrates how an open and constructive dialogue among European 
stakeholders has positively influenced therapy development for DMD, and how this could serve 





1. Introduction  
Developing therapies for genetic diseases poses unique challenges as illustrated by the example 
of Duchenne muscular dystrophy (DMD), a rare, progressive, muscle-wasting disease affecting 
about 1 in 5000 new-born boys 1;2. DMD is caused by mutations abolishing production of the 
muscle fiber stabilizing protein dystrophin. Many experimental therapeutic strategies are being 
pursued. However, when some of these transitioned into the clinical trial phase, crucial elements 
for their evaluation were lacking, including comprehensive natural history data, meaningful 
outcome measures assessing clinical benefit, their correlation with natural history data, and 
pharmacodynamic biomarkers. During a seminal meeting organized by the European Union (EU) 
funded (FP6) network of excellence TREAT-NMD (www.treat-nmd.eu) and hosted by the 
European Medicines Agency (EMA) in 2009 3 major bottlenecks were identified. This meeting 
gave rise to a cooperative effort among patients and advocacy groups, academics, health care 
professionals and industry aimed at collecting the missing data and the development of the tools 
needed. At the same time, EU  regulators commenced developing guidelines to support the 
development of medicinal products for the treatment of Duchenne and Becker muscular 
dystrophy 4;5. 
This review will use the example of DMD to outline how the collaborative effort of 
stakeholders in Europe can stimulate and assist orphan medicine development in the EU, with a 
focus on developing functional outcome measures, biomarkers and regulatory guidelines and on 
collecting longitudinal natural history data. Finally, the review will discuss future aspects of 
DMD therapy development.  
Panel 1: Aims of this policy view 
 To identify challenges in Duchenne muscular dystrophy therapy development 
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 To outline the collaborative effort of Duchenne muscular dystrophy stakeholders to 
develop tools and collect data to address the challenges and have this effort serve as a 
paradigm for other rare diseases  
 To identify and prioritize future efforts for Duchenne muscular dystrophy therapy 
development 
2. Duchenne muscular dystrophy and therapeutic strategies 
DMD is caused by mutations in the dystrophin encoding DMD gene 6. Lacking functional 
dystrophin, muscle fibres are more susceptible to damage resulting in chronic damage and 
replacement by connective and fat tissue, causing progressive muscle wasting and weakness 6-8.  
There is currently one compound (Translarna) that has received conditional marketing 
authorization in the EU for the treatment of ambulant DMD patients of 5 years and older with a 
nonsense mutation (causative mutation in ~13% of patients)7;9;10. Numerous additional therapies 
are in clinical development, many of which have obtained orphan medicine designation in the 
EU (Supplementary Table 1). Exon skipping, the most advanced approach, aims to correct the 
disrupted reading frame in dystrophin transcripts, allowing production of a partially functional 
dystrophin, as found in the less progressive Becker muscular dystrophy 11. Exon skipping is 
induced by short, chemically modified DNA analogues (antisense oligonucleotides (AON)). 
Because mutations cluster, skipping certain exons applies to relatively large groups of patients 
7;10. A marketing authorization application has been filed with EMA for an AON targeting exon 
51 (applicable to ~ 13% of patients) 7;10. 
3. DMD Care standards 
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DMD affects primarily skeletal, respiratory and cardiac muscles. It has a predictable clinical 
progression with onset in early childhood when boys present with delayed motor milestones and 
early signs of muscle weakness, followed by the irreversible loss of the ability to walk, self-feed, 
sit independently and breathe without assisted ventilation (Figure 1). These events are life-
changing for affected children and parents, with patients relying on full-time help in the later 
stages of the disease. Cardiac problems progress inevitably, leading to severe cardiomyopathy 
and early death.  
Standards of care have been generated and disseminated in a collaborative effort of 
patient organisations and TREAT-NMD which was coordinated and supported by the US 
Centers for Disease Control and Prevention (CDC) 12-14. Multidisciplinary care (Table 1) 
focusing on all different aspects of the disease has resulted in a slower disease progression, 
extending mean life span to the 3rd – 4th decade, when death generally occurs due to respiratory 
or heart failure. Nevertheless, recent evidence shows that in several European countries many 
adult and paediatric DMD patients receive sub-optimal care 15;16 and that care standards for 
adults need to be developed further 17. From large, multicentre trials it is becoming increasingly 
clear that variability in care generates noise in outcome parameters 18-20.  
DMD has evolved from a pediatric disease to a severe and chronic adult condition. With 
increasing age, the management of swallowing and feeding difficulties, smooth muscle involvement 
with bladder and intestinal dysfunctions, and issues of social integration and quality of life will 
require further attention. A coordinated, multidisciplinary approach addressing all factors that will 
determine health and quality of life, should be further guaranteed in the transition to adult care. 
4. The regulatory process in the EU 
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4.1 Benefit-risk assessment 
EU legislation requires that marketing authorization for a medicinal product is refused if the 
benefit-risk balance is not considered favorable, if therapeutic efficacy is insufficiently 
substantiated or if the qualitative and quantitative composition of the medicinal product is not 
appropriately controlled. Assessment of quantified and well understood benefits and risks of a 
potential therapy is therefore key in the process of medicine regulation. To enable regulators to 
conclude on benefit-risk ratio, reliable measurements to identify and quantify benefits and risks 
need to be provided. Subjective judgement, input from stakeholders and previous decisions for 
other products in the field also contribute to benefit-risk assessment. Regulators have adopted a 
systematic and structured approach to benefit-risk assessment, to make their decisions as explicit 
and transparent as possible. For products that received marketing authorization, EMA provides 
relevant information on the benefit-risk assessment in the European Public Assessment Report 
(EPAR). In addition, patients’ participation in benefit-risk evaluation is ensured through a 
framework allowing them to actively participate in regulatory workshops, scientific advisory 
groups, scientific advice meetings and committee discussions 21;22. 
4.2.Regulatory tools  
Regulatory tools are in place to facilitate the development of medicinal products. Disease 
specific guidelines describe regulators’ preferences and standards for the demonstration of 
quality, safety and efficacy of medicines. For DMD a draft ‘Guideline on the clinical 
investigation of medicinal products for the treatment of Duchenne and Becker Muscular 
Dystrophy’ was published by EMA in March 2013 4, discussed amongst stakeholders during a 
workshop 23 and has now been published 5. Furthermore, the Food and Drug Administration 
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(FDA, US) recently published draft guidelines as well (consultation period ended August 8, 
2015).  
Regulatory agencies also provide scientific advice at any stage of development of a 
medicinal product to help investigators perform appropriate studies to support a future marketing 
authorisation. In addition, the EU offers a range of incentives to specifically encourage the 
development of orphan medicines (Table 2). 
For rare diseases such as DMD, increased levels of uncertainty on benefits and risks are 
more likely to be identified at the time of the assessment. However, specific approval 
mechanisms exist in the EU to enable early access to medicines fulfilling an unmet medical need 
in a fatal disease like DMD, subject to the provision of post-marketing data (e.g. conditional 
approval) 25. Furthermore, the EU regulation on orphan medicinal products provides market 
exclusivity for 10 years for a product that has obtained a marketing authorization 24 .  
Additionally, EMA is developing a scheme for priority medicines (PRIME), to optimise 
the development and accelerated assessment of medicinal products of major public health 
interest, such as rare diseases. The scheme is based on enhanced interaction and early dialogue 
with medicine developers. The EMA expects to launch PRIME in the first quarter of 2016 26. 
5. Outcome measures 
The primary pathophysiological effect of DMD is a decline in muscle strength and motor 
function and these are therefore important parameters to measure. Any potential outcome 
measure to be used in DMD should be able to reliably detect and quantify a clinically meaningful 
effect on patients 23.  
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5.1 Functional outcome measures in DMD 
The regulatory requirements in the EU postulate that an observed treatment effect needs to lead 
to a clear clinical benefit. Consequently functional improvement or delay of progression and 
deterioration is considered a relevant outcome for DMD patients. 
To assess gross motor function, the 6 minute walk test (6MWT) and the North Star 
Ambulatory Assessment (NSAA) are used as primary endpoints in most trials in ambulant DMD 
boys 27;28. A subset of ambulant DMD patients with behavioural and cognitive problems cannot 
comply with these assessments, but well defined inclusion and exclusion criteria will help to 
enrol those patients willing and able to comply with all clinical trial protocol requirements and 
procedures. When the first trials for DMD were initiated, the availability of detailed longitudinal 
data for the 6MWT was limited. Due to coordinated efforts of stakeholders, data are now 
published, describing the evolution over 12, 24 and 36 months in natural history studies 
performed in Italy and Belgium and by the Cooperative International Neuromuscular Research 
Group (CINRG) 10;29-32. Based on this one can depict longitudinal performance: young boys 
show some improvement in their 6MWT and NSAA scores up to the age of 7, whiles afterwards 
deterioration usually occurs 27;29;32. Similar results have been observed using cut off values at 
baseline for the 6MWT (above/below 350 meters) 27;29;32. The combination of these two variables 
allowed the identification of distinct trajectories of progression in different subgroups subdivided 
by age and baseline values, which can be useful for interpretation of clinical trial results, 
however the acceptability of historical controls in the pivotal trials in DMD is still a matter of 
discussion with the regulators 23;33.  
The rate of decline and its predictive value on subsequent loss of ambulation has been 
established for the NSAA from a large database in the UK (UK North Star network) and for the 
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6MWT using data from CINRG and this was useful in the postulation of their expected minimal 
clinical important difference (MCID) 27 27;29;32;34. Furthermore, knowing the rate of decline and 
expected variation enables stratification and power calculations. It is recommended that any 
target effect size is discussed in advance with the regulators, to help define the expectations and 
agree on what constitutes a clinically relevant change in a given experimental setting. 
Evaluation of the quality of life is an important aspect of treatment evaluation as well. In 
DMD patients a strong correlation was shown between the 6MWT and the global Pediatric 
Outcome Data Collection Instrument (PODCI) - a health-related quality of life measure of 
functional ability. Notably, even at high levels of disability, smaller increases in the 6MWT 
result in a meaningful change in quality of life scores 34.   
5. 1.2 New functional outcome measure scales 
By definition, the 6MWT and NSAA cannot be used in non-ambulant individuals. Given that the 
average age at loss of ambulation is ~10.5 years35 and the median survival of patients is ~30 
years36;37, it follows that the majority of the DMD population is non-ambulant. To address this, a 
collaborative international group including DMD boys and their families developed the 
Performance of Upper Limb (PUL) scale to evaluate upper limb function in ambulant and non-
ambulant DMD patients 38-40. The scale has been validated for clinical use against other 
functional measures such as the 6MWT 41 and longitudinal data are emerging across ambulant 




Studies have been conducted using neurodevelopmental scales in young DMD boys, in 
some instances even from the neonatal period 43-45, showing that DMD boys have delayed motor 
milestones most markedly in the gross locomotor and language subscales and that the gap with 
age-matched peers increases with age for motor skills. This has led to the understanding among 
stakeholders that should therapeutic interventions be proven effective and safe, it would be 
important to administer them as early as possible.  
5.2 Biomarkers and surrogate endpoints 
Biomarkers are important tools to inform and guide medicine development and have regulatory 
applications, e.g. to confirm mechanism of action (pharmacodynamics biomarker). When a clear 
relationship with clinical outcomes has been established, they can even be used as a primary 
outcome measures (surrogate endpoints) instead of a functional outcome measure. Because 
biomarkers are objectively measured, they are less prone to variation from factors like 
motivation and compliance with functional tests. However, to fit with regulatory requirements, 
biomarkers must be validated for a certain context of use (e.g. trial enrichment, surrogate 
endpoint etc.). A dedicated procedure is in place at EMA for the qualification of biomarkers and 
novel methodologies to use in the context of research and development of pharmaceuticals 46;47.  
5.2.1 Dystrophin 
Measuring dystrophin protein production was considered an obvious choice for a 
pharmacodynamic marker in trials with a compound aiming at dystrophin re-expression and 
dystrophin detection has been used as a secondary endpoint in early phase dose escalation studies 
for exon skipping therapies and Translarna 48-52. In practice, however, it became apparent that 
dystrophin quantification is not straightforward (reviewed in 53).  
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To use dystrophin as a pharmacodynamics biomarker, it will be crucial that dystrophin 
quantification methods are proven to be reliable and reproducible. Recent efforts of an 
international working group have demonstrated that by utilizing a carefully devised standard 
operating procedure, and sharing (in a blinded fashion) the same material, it is possible to stratify 
patients with different levels of dystrophin production accurately, with good intra- and inter-
laboratory reliability and with good correlation between western blot and immunocytochemistry 
54 using several dystrophin quantification protocols 55-57. Further improvements to decrease the 
coefficients of variations (especially for low dystrophin levels) for these techniques are an 
important next step in validating dystrophin as a pharmacodynamic biomarker for therapeutic 
efficacy.  
Currently, insufficient data are available to establish a clear correlation between 
dystrophin levels and muscle function for various stages of disease, thus making their use as a 
surrogate primary endpoint questionable.  
5.2.2 Magnetic resonance imaging 
Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) techniques 
are promising tools for quantifying disease pathology and progression in a non-invasive and 
longitudinal fashion. Over the past years, protocols have been developed and validated on 
numerous different MR-platforms to measure muscle edema and inflammation 58-61. Now that 
protocols are validated across platforms and sites, MRI and MRS can be used as quantitative, 
and in most cases exploratory, outcome measures in a number of ongoing natural history studies 
and interventional trials. Specialized protocols to quantitatively assess treatment effects have 
been tested independently globally across neuromuscular centers and the first promising results 
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have now been published 58-62. The ImagingDMD consortium in the US, led by Krista 
Vandenborne and Lee Sweeny and supported by various patient organisations and the NIH, has 
collected longitudinal data in a large cohort of DMD patients and demonstrated that MR 
measures of T2 and lipid fraction show excellent sensitivity to detect DMD disease pathology 
and progression, even in younger boys where functional outcomes improve with time 63. 
Furthermore, MRI/MRS is able to detect therapeutic effects of corticosteroids in reducing 
inflammatory processes in skeletal muscles of boys with DMD 64. As such, MRI shows promise 
as a surrogate outcome measure, although more natural history data need to be collected. 
6. Extrapolation 
Due to the impact of disease stage and age on functional outcome measures in DMD, it is 
important to have well-defined and homogeneous patient cohorts in clinical trials. This can 
reduce patients’ variability in function, which is crucial for reliably identifying a treatment effect 
in a specific population. However, it can also affect the indication for which the drug can 
potentially be approved, because sufficient evidence needs to be available to allow for a separate 
benefit-risk ratio conclusion in other subgroups of patients (e.g. per disease stage, ambulant vs. 
non-ambulant).  
Currently, most DMD trials are conducted in patients who can comply with the 6MWT, 
i.e. ambulant patients of 5 years and older (~20-25% of the entire patient population). As 
mentioned, earlier treatment is anticipated to lead to a larger therapeutic effect. Nevertheless, 
non-ambulant patients would certainly also benefit from a slower deterioration of their residual 
muscle function (motor, respiratory, cardiac) and therefore an indication including non-ambulant 
patients would be a preferable goal.  
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The extrapolation of data from a trial performed in a certain sub-group to a different 
patient population (e.g. younger or older patients) will have to be discussed with the regulators 
on a case-by-case basis. The current position of the EMA is that if supported by the mechanism 
of action, extrapolation from older to younger (or from younger to older) patients might be 
discussed in the context of additional real life data needed to be collected post-authorisation. 
When data is generated in a subset of the patient population, it is likely that, to obtain a broad 
license, in addition to showing efficacy there will be the need to generate data on 
pharmacokinetic and pharmacodynamics parameters and safety in patients outside this subset to 
address the outstanding uncertainties for the other subsets. These aspects are increasingly 
discussed but for any further consideration a committee for human medicinal products (CHMP) 
scientific advice should be sought to discuss the most appropriate strategy for development. 
7. Future perspectives 
Since the first meeting with the European regulators in 2009 3, the DMD academic and patient 
communities have become more aware of the regulatory processes. In collaboration with 
pharmaceutical companies working in the DMD field, they have tried to address the gaps 
identified at the time. Large amounts of data have been collected and new outcome measures and 
tools were developed building on the existing resources, such as patient registries, provided by 
patient organisations and TREAT-NMD 7;65-67. At the same time the regulators have become 
more familiar with the specifics of the development of new medicines in DMD and have 
finalized guidelines on medicine development in DMD and Becker muscular dystrophy 5.  
The improved mutual understanding was helpful for a continuous and constructive dialogue 
that has moved the field forward. A recent stakeholder meeting (London, April 2015) allowed for 
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further alignment of ongoing work and prioritization of future efforts. These include the 
following: 
1. Efforts to increase international awareness of DMD care standards need to continue, first and 
foremost because patients deserve access to optimal care. Plans to set up a European 
Reference Network for neuromuscular disorders will build on the TREAT-NMD care and 
trial site registry (CTSR) 66 and the CARE-NMD project 16 and facilitate the implementation 
of DMD care standards throughout Europe. This would complement efforts the Parent 
Project Muscular Dystrophy (PPMD) is currently coordinating in the US to certify centres 
that provide care according to international guidelines68.  
2. New centres participating in trials are needed. Many clinical trials are currently conducted in 
the DMD field, resulting in capacity problems in experienced trial sites. Adhering to the care 
standards is a first prerequisite to be selected as a trial site by companies.  
3. Another PPMD-led initiative is defining core sets of outcome measures to be used in 
ambulant and non-ambulant patients, which ideally should be used in all DMD trials. This 
would facilitate the DMD trial process, because personnel will have to be trained only once 
rather than for each trial. Furthermore, it would allow comparison of results between 
different trials and facilitate post-marketing surveillance.  
4. Regulators offer scientific and regulatory guidance. Platforms are available to discuss 
specific medicine development, development of biomarkers, functional outcome measures, 
patient reported outcomes (PROs) etc. Through an increased dialogue, advice will be sought 
from EMA towards qualification of outcome measures in DMD (e.g. PUL as a functional 
outcome measure in non-ambulant patients and MRI as a biomarker or surrogate endpoint for 
DMD). The same platform could be considered for the quantification of dystrophin 
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expression as a pharmacodynamic biomarker, which has recently been discussed at an FDA 
and National Institute of Health organized workshop on this topic 69.  
5. Developing a therapy for a rare disease like DMD should be a global effort, which implies 
adequate alignment of regulatory requirements, as well as continued communication among 
the regulatory bodies in the different regions (EMA, FDA, PMDA, Health Canada etc.) e.g. 
on guidelines for DMD therapy development and biomarker qualification 70.   
6. Publication of data in peer reviewed journals is critical, because this informs the scientific 
community and regulatory bodies, allowing data to be used in guideline development, 
scientific advice and medicine assessment. The field already made an effort to publish on 
natural history and functional outcome measures in ambulant patients and have started 
publishing on MRI as a potential biomarker for muscle quality. A focus should now also be 
on producing natural history data and outcome measures for non-ambulant patients (e.g. 
upper limb function scales, heart and respiratory function). 
7. Placebo-controlled trials are currently required to study safety and efficacy of new therapies. 
However, it is not excluded that in the future natural history data or data from the placebo 
arm of other trials can be used. Notably, several large natural history studies are being 
conducted, e.g. one sponsored by BioMarin Pharmaceutical Inc. and one sponsored by the 
Association Française contre les Myopathies (AFM). It will be critical to align the outcome 
measures used in ongoing natural history studies and clinical trials and for the groups 
involved to share the datasets. Currently several initiatives to collect and curate these datasets 
are ongoing.  
8. Most clinical trials are done in selected populations of DMD patients, generally ambulant 
patients. However, to allow for the extrapolation of efficacy and safety to obtain a broader 
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indication (e.g. for all DMD patients when the trial was focused on a specific group of 
ambulant boys), the collection of data to validate the extrapolation exercise would be crucial. 
As mentioned, data collected in patients outside the inclusion criteria of the trial population 
will be required. For this the natural history data collection and outcome measure 
development will be increasingly important as well for the effective assessments in post 
marketing studies.   
8. Conclusion 
The collaborative effort of researchers, health care professionals and representatives from 
industry, regulators and the patient community has been instrumental in moving the DMD field 
forward in Europe (see panel 2 for take home messages). In parallel comparable efforts are 
ongoing in the USA (e.g. the Action Plan for Muscular Dystrophies 71) and the FDA has 
programs for clinical outcome assessment, biomarker qualification and providing regulatory 
guidance as well72-74. Nevertheless, the work is not yet complete and new focus areas have been 
identified (section 7). Each of these priority areas will require continued involvement from 
researchers, healthcare professionals, and representatives from industry, regulators and the 
patient community. While these tasks may seem challenging, there is a strong basis of prior 
work, mutual understanding and collaboration that will aid these efforts. While prior work 
primarily focused on conducting trials to obtain marketing authorization, the field has now 
started to address challenges around post marketing and treatment access strategies.  
 
Panel2: Take home messages 
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 A collaborative and constructive dialogue between patient representatives, academics, 
industry and regulators can facilitate and accelerate therapy development for rare diseases 
 For rare diseases, development and implementation of standards of care to decrease 
variability is crucial for multicentre trials  
 Functional and molecular outcome measures should be developed in collaboration with 
patient representatives and regulators 
 High quality data on natural history and outcome measures are crucial for clinical trial 
design and regulatory approval, and should ideally be developed prior to or in parallel 
with potential therapies 
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Legends to Figures 
Figure 1. Schematic depiction of disease milestones 
 
Tables 
Table 1: Summary of care aspects for DMD patients 
 A coordinated multidisciplinary medical, surgical and rehabilitative approach of symptoms, 
from diagnosis on, is required to proactively address all medical aspects and co morbid 
conditions of DMD. Care considerations have been published 12;13, family friendly versions 
and multiple languages are available on the TREAT-NMD website (http://www.treat-
nmd.eu/care/dmd/family-guide/translations/). Imperatives for DMD care were generated 
by TREAT-NMD in collaboration with DMD patient organisations (http://www.treat-
nmd.eu/care/dmd/imperatives-dmd/)(Rodger et al, submitted manuscript). 
 Genetic confirmation of diagnosis is needed to enable genetic counseling. Psychological 
support and patient organization contact information should be offered to parents upon 
diagnosis. 
 Treatment with glucocorticosteroids (GCS) is accepted as standard of care and initiated at a 
young age, at least before the child is starting to decline (between age 3 to 6 years). 
Different steroid regimens and compounds are in use with different effect and side effect 
profiles. Most commonly used are prednisone 0.75 mg/kg/daily or Deflazacort 0.9 
mg/kg/daily, but intermittent dosages and on /off schedules are used as well to manage 
side effects. 
 Common practice is continuation of monitored treatment after loss of ambulation, aiming at 
preventing the development of scoliosis and at delaying loss of upper limb function and 
cardio-respiratory manifestations. Optimal care includes the prevention, monitoring and 
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treatment of the side effects of long term chronic GCS use, such as excessive weight gain, 
hypertension, osteoporosis, impairment of glucose metabolism, delayed puberty and 
cataract. 
 Physiotherapy aiming at contracture prevention and management should be integrated in 
daily life from a young age 
 Orthopedic management includes monitoring spine deformity and timely spine surgery for 
curves > 30-40° 
  Improved pulmonary management has strongly impacted on quality of life and survival. 
Decline in respiratory function should be monitored with timely provision of airway 
clearance assistance and non-invasive ventilatory support to palliate symptoms of 
inefficient cough and hypoventilation 
 Cardiac involvement is observed from an early age and may become symptomatic in the 
second decade. Pharmacological symptomatic treatment for cardiac manifestations includes 
the standard treatments of dilated cardiomyopathy and arrhythmia (angiotensin converting 
enzyme (ACE) inhibitors, beta –blockers and diuretics). Encouraging data are emerging on 
the protective effect of after load reduction by treatment with ACE inhibitors, before left 
ventricular function is affected. 
Table 2. Orphan medicinal product designation and incentives in the EU24$ 
The designation procedure and criteria are laid down in regulation (EC) No 141/2000 
 Criteria for designation 
o Product is intended for the diagnosis, prevention or treatment of a life-threatening 
or chronically debilitating condition affecting <1 in 2,000 persons in the EU OR a 
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condition that is life-threatening, seriously debilitating and/or chronic for which it 
is unlikely that products would be marketed without incentives 
o A product for diagnosis, prevention or treatment of the condition does not exist, 
or if it does, the new product will be of significant benefit 
 Incentives once designation has been obtained 
o Access to free protocol assistance by the EMA 
o Products will be authorised via a centralised procedure (valid in all EU countries, 
Iceland, Liechtenstein and Norway); fee reductions for marketing authorization 
applications apply 
o Upon marketing authorization, products have 10 year market exclusivity over 
similar products, unless these are clinically superior or safer than the marketed 
product 
$This is a summary only. For complete information we refer the reader to: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_00002
9.jsp&mid=WC0b01ac05800240ce   
  
Supplementary Table 1. Overview of substances with orphan drug designation for DMD 
 
